Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Tumor-Agnostic 1Thoracic 1Lymphoid 1Genitourinary 1Breast 1

Conditions

Rectal Neoplasms 1Prostatic Neoplasms 1Neoplasms 1

Interventions

Docetaxel 229Radiotherapy 206Magnetic Resonance Spectroscopy 204Radiosurgery 176Gemcitabine 155pembrolizumab 150Nivolumab 147enzalutamide 140Prednisone 129Cisplatin 123Leuprolide 119Androgen Antagonists 117Abiraterone Acetate 114Sunitinib 106Specimen Handling 94Surveys and Questionnaires 91Goserelin 91bicalutamide 90Carboplatin 88Ipilimumab 82gallium 68 PSMA-11 80Blood Specimen Collection 78Everolimus 73apalutamide 72Radiation 71Standard of Care 68Biopsy 68acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 66Paclitaxel 64Cyclophosphamide 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Rifaximin × Genitourinary × Clear all
NCT06783153 2025-01-20

Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients

Mansoura University

Phase 1/2 Not yet recruiting
80 enrolled
GastrointestinalGenitourinary

Neoplasms, Prostatic Neoplasms, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡